Samuel Brady

Associate Professor, Clinical Medical Physicist

Cincinnati Children's Hospital Medical Center
Country flagUnited States

Research Interests

ApplyKite TwinLearns as you apply

Make your next move.

Prepare your application

Review drafts before you send them.

Explore related searches

About

Dr. Samuel Brady is an Associate Professor and Clinical Medical Physicist at Cincinnati Children's Hospital Medical Center in the United States. His research focuses on radiation dose management in pediatric imaging, advancements in imaging technologies, and the application of artificial intelligence in medical physics. Recent articles authored by Dr. Brady address topics such as radiation dose alerts for pediatric cardiac procedures, continuous glucose monitoring post-radiologic exposure, and deep learning techniques for image reconstruction and segmentation in pediatric CT scans.

Articles (9)

Relapse remains the leading cause of mortality in pediatric acute myeloid leukemia (AML), yet the genetic changes contributing to relapse remain incompletely defined. To address this gap, we performed whole-genome sequencing and targeted-capture sequencing on 39 diagnosis–relapse and 2 relapse–relapse pairs of pediatric AML. Mutational burden increased at relapse, largely reflecting spontaneous mutagenesis, whereas therapy-related signatures were rarely observed and only occasionally associated with pathogenic mutations. Although recurrently enriched mutations at relapse included those in FLT3 , WT1 , and TP53 , relapse-fated subclones were frequently marked only by non-pathogenic or non-coding variants. Longitudinal deep sequencing in eight patients showed rapid depletion of major clones after induction therapy, whereas subclones often displayed variable chemosensitivity. Relapse-specific mutations emerged only late or remained undetectable during remission, suggesting that clonal selection of pre-existing clones is the predominant mechanism of relapse. Transcriptome analysis of paired RNA sequencing data revealed no differentially expressed genes, but gene set enrichment analysis and CIBERSORT deconvolution in each pair uncovered heterogeneous trajectories to relapse. Although relapse is often attributed to the emergence of stem-like phenotypes, our data demonstrate that transcriptional evolution is more diverse: some cases acquired stem-like features, whereas others showed partial differentiation, which was confirmed by re-analysis of a public single cell RNA sequence dataset. These changes were largely constrained by baseline differentiation states at diagnosis. Together, our data indicate that pediatric AML relapse arises through selection of pre-existing clones with diverse trajectories, underscoring the need to target both stem-like and differentiated populations to achieve durable cures.

Year:

2025

Background Increased positron emission tomography (PET) scanner z -axis coverage provides an opportunity in pediatrics to reduce dose, anesthesia, or repeat scans due to motion. Objective Recently, our digital PET scanner was upgraded from a 25-cm to a 30-cm z -axis coverage. We compare the two systems through National Electrical Manufacturing Association (NEMA) testing and evaluation of paired images from patients scanned on both systems. Materials and methods NEMA testing and a retrospective review of pediatric patients who underwent clinically indicated 18F-fluorodeoxyglucose (FDG) PET computed tomography (PET/CT) on both systems with unchanged acquisition parameters were performed. Image quality was assessed with liver signal to noise ratio (SNR-liver) and contrast to noise ratio (CNR) in the thigh muscle and liver with results compared with an unpaired t -test. Three readers independently reviewed paired (25 cm and 30 cm) images from the same patient, blinded to scanner configuration. Results Expansion to 30 cm increased system sensitivity to 29.8% (23.4 cps/kBq to 30.4 cps/kBq). Seventeen patients (6 male/11 female, median age 12.5 (IQR 8.3–15.0) years, median weight 53.7 (IQR 34.2–68.7) kg) were included. SNR-liver and CNR increased by 35.1% (IQR 19.0–48.4%) and 43.1% (IQR 6.2–50.2%) ( P -value <0.001), respectively. All readers preferred images from the 30-cm configuration. A median of 1 (IQR 1–1) for fewer bed positions was required with the 30-cm configuration allowing a median of 91 (IQR 47–136) s for shorter scans. Conclusion Increasing z -axis coverage from 25 to 30 cm on a current-generation digital PET scanner significantly improved PET system performance and patient image quality, and reduced scan duration.

Year:

2024

Year:

2024

Background . The increasing use of continuous glucose monitor (CGM) necessitates a review of variables that impact accuracy and interrupt use. Manufacturer recommendations include removing CGMs before diagnostic imaging, such as X‐ray and computed tomography (CT). Early removal and replacement of CGM components present financial, clinical, and psychosocial burdens to the wearer and interrupt optimal management of diabetes for pediatric patients who receive a total pancreatectomy with islet autotransplantation (TPIAT). The study’s aim was to evaluate the effect of scatter dose exposure during X‐ray or CT if the CGM remained intact but outside the field of view (FoV). Materials and Methods . Participants were followed through the first 3 months after TPIAT surgery, managed diabetes with an insulin pump and CGM, and were routinely exposed to diagnostic imaging. Participants’ CGMs were unshielded by a protective apron during any X‐ray or CT procedures for the duration of the study period, and the transmitter was collected after expiration or removal. Glucometer data was collected from hospital records and home glucometer downloads. Mixed models were used to analyze absolute differences between matched CGM and glucometer values, and Clarke error grid analyses (EGA) were performed. Scatter dose exposure was derived using anthropomorphic phantoms and calculated retrospectively. Results . A total of 14 patients (median 12.2 years, 64% female) received a median of five diagnostic imaging procedures with a median cumulative scatter dose of 559 µ Gy. The absolute difference between the CGM and glucometer values was not significantly associated with the cumulative scatter dose ( p = 0.17) or time from TPIAT ( p = 0.24) when analyzed in a mixed model. Regardless of scatter dose exposure, time from TPIAT, or glucometer, ≥98% of glucose values fell within zones A and B on EGA. Conclusion . Scatter dose exposure from diagnostic imaging did not affect the clinical accuracy of CGM values for the duration of transmitter use. Leaving CGM components in place when not in the FoV during diagnostic imaging successfully mitigated interruptions to use and undue burden or cost to participants.

Year:

2024

Year:

2023

Year:

2022

Year:

2021

Year:

2021

Year:

2021

Collaborators (5)

Seth Karol

Associate Member, Leukemia & Lymphoma Division

St. Jude Children's Research Hospital

UNITED STATES
View details

Tanja A. Gruber

Stanford University

UNITED STATES
View details

Joseph Meier

Assistant Professor

Cincinnati Children's Hospital Medical Center

UNITED STATES
View details

Lu Wang

Medical Director, Molecular Pathology

St. Jude Children's Research Hospital

UNITED STATES
View details

Pandurang Kolekar

Sr. Computational Research Scientist

St. Jude Children's Research Hospital

UNITED STATES
View details